Cystamine metabolism and brain transport properties: Clinical implications for neurodegenerative diseases

Journal of Neurochemistry

Volumn 114, Issue 6, 2010, Pages 1651-1658

  Bousquet, Mélanie ^a,b   Gibrat, Claire ^a   Ouellet, Mélissa ^a,b   Rouillard, Claude ^a,b   Calon, Frédéric ^a,b   Cicchetti, Francesca ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

cysteamine; cysteine; HPLC; hypotaurine; in situ cerebral perfusion; taurine

Indexed keywords

CYSTAMINE; CYSTEINE; HYPOTAURINE; MERCAPTAMINE; PHOSPHATE BUFFERED SALINE; TAURINE; NEUROPROTECTIVE AGENT;

ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; BRAIN FUNCTION; BRAIN PERFUSION; DEGENERATIVE DISEASE; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; C57BL MOUSE; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

MUS;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CYSTAMINE; CYSTEAMINE; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; TAURINE;

EID: 77956320467     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06874.x     Document Type: Article

References (42)

1. Bacq Z. M. Beaumariage M. L. (1965) Radioprotective action of cysteamine and cystamine in mice as a function of the period of time between injection of the protector and the start of X-Ray irradiation. Arch. Int. Pharmacodyn. Ther. 153, 457 459.
2. Benrabh H., Bourre J. M. Lefauconnier J. M. (1995) Taurine transport at the blood-brain barrier: an in vivo brain perfusion study. Brain Res. 692, 57 65.
3. Borrell-Pages M., Canals J. M., Cordelieres F. P. et al. (2006) Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J. Clin. Invest. 116, 1410 1424.
4. Bouckenooghe T., Remacle C. Reusens B. (2006) Is taurine a functional nutrient? Curr. Opin. Clin. Nutr. Metab. Care 9, 728 733.
5. Bourasset F., Cisternino S., Temsamani J. Scherrmann J. M. (2003) Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier. J. Neurochem. 86, 1564 1567.
6. Calon F., Morissette M., Goulet M., Grondin R., Blanchet P. J., Bedard P. J. Di Paolo T. (1999) Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content. Neurochem. Int. 35, 81 91.
7. Cavallini D., Scandurra R. Demarco C. (1963) The enzymatic oxidation of cysteamine to hypotaurine in the presence of sulfide. J. Biol. Chem. 238, 2999 3005.
8. Coloso R. M., Hirschberger L. L., Dominy J. E., Lee J. I. Stipanuk M. H. (2006) Cysteamine dioxygenase: evidence for the physiological conversion of cysteamine to hypotaurine in rat and mouse tissues. Adv. Exp. Med. Biol. 583, 25 36.
9. Dagenais C., Rousselle C., Pollack G. M. Scherrmann J. M. (2000) Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J. Cereb. Blood Flow Metab. 20, 381 386.
10. Dedeoglu A., Kubilus J. K., Jeitner T. M. et al. (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 22, 8942 8950.
11. Dohil R., Fidler M., Gangoiti J. A., Kaskel F., Schneider J. A. Barshop B. A. (2009) Twice-daily cysteamine bitartrate therapy for children with cystinosis. J. Pediatr. 156, 71 75.
12. Dominy J., Eller S. Dawson R. Jr. (2004) Building biosynthetic schools: reviewing compartmentation of CNS taurine synthesis. Neurochem. Res. 29, 97 103.
13. Dominy J. E. Jr. , Simmons C. R., Hirschberger L. L., Hwang J., Coloso R. M. Stipanuk M. H. (2007) Discovery and characterization of a second mammalian thiol dioxygenase, cysteamine dioxygenase. J. Biol. Chem. 282, 25189 25198.
14. Dubinsky R. Gray C. (2006) CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease. Mov. Disord. 21, 530 533.
15. Ewetz L. Sorbo B. (1966) Characteristics of the cysteinesulfinate-forming enzyme system in rat liver. Biochim. Biophys. Acta 128, 296 305.
16. Fox J. H., Barber D. S., Singh B. et al. (2004) Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J. Neurochem. 91, 413 422.
17. French E. D., Vezzani A., Whetsell W. O. Jr. Schwarcz R. (1986) Anti-excitotoxic actions of taurine in the rat hippocampus studied in vivo and in vitro. Adv. Exp. Med. Biol. 203, 349 362.
18. Gibrat C., Bousquet M., Saint-Pierre M., Levesque D., Calon F., Rouillard C. Cicchetti F. (2010) Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor. Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 193 203.
19. Green H. (1993) Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism. Cell 74, 955 956.
20. Huxtable R. J. (1992) Physiological actions of taurine. Physiol. Rev. 72, 101 163.
21. Jeitner T. M., Delikatny E. J., Ahlqvist J., Capper H. Cooper A. J. (2005) Mechanism for the inhibition of transglutaminase 2 by cystamine. Biochem. Pharmacol. 69, 961 970.
22. Karpuj M. V., Becher M. W., Springer J. E., Chabas D., Youssef S., Pedotti R., Mitchell D. Steinman L. (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8, 143 149.
23. Lee J. I., Londono M., Hirschberger L. L. Stipanuk M. H. (2004) Regulation of cysteine dioxygenase and gamma-glutamylcysteine synthetase is associated with hepatic cysteine level. J. Nutr. Biochem. 15, 112 122.
24. Leonardi R., Zhang Y. M., Rock C. O. Jackowski S. (2005) Coenzyme A: back in action. Prog. Lipid Res. 44, 125 153.
25. Martignoni M., Groothuis G. M. de Kanter R. (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol. 2, 875 894.
26. Muramatsu M., Kakita K., Nakagawa K. Kuriyama K. (1978) A modulating role of taurine on release of acetylcholine and norepinephrine from neuronal tissues. Jpn. J. Pharmacol. 28, 259 268.
27. Oja S. S. Saransaari P. (1996) Taurine as osmoregulator and neuromodulator in the brain. Metab. Brain Dis. 11, 153 164.
28. Oldendorf W. H. Szabo J. (1976) Amino acid assignment to one of three blood-brain barrier amino acid carriers. Am. J. Physiol. 230, 94 98.
29. Ouellet M., Emond V., Chen C. T., Julien C., Bourasset F., Oddo S., LaFerla F., Bazinet R. P. Calon F. (2009) Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: an in situ cerebral perfusion study. Neurochem. Int. 55, 476 482.
30. Pasantes-Morales H., Arzate N. E. Cruz C. (1981) The role of taurine in nervous tissue: its effects on ionic fluxes. Adv. Exp. Med. Biol. 139, 273 292.
31. Pinto J. T., Van Raamsdonk J. M., Leavitt B. R., Hayden M. R., Jeitner T. M., Thaler H. T., Krasnikov B. F. Cooper A. J. (2005) Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. J. Neurochem. 94, 1087 1101.
32. Pinto J. T., Khomenko T., Szabo S., McLaren G. D., Denton T. T., Krasnikov B. F., Jeitner T. M. Cooper A. J. (2009) Measurement of sulfur-containing compounds involved in the metabolism and transport of cysteamine and cystamine. Regional differences in cerebral metabolism. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877, 3434 3441.
33. Pitari G., Maurizi G., Flati V., Ursini C. L., Spera L., Dupre S. Cavallini D. (1992) Enzymatic synthesis of S-aminoethyl-L-cysteine from pantetheine. Biochim. Biophys. Acta 1116, 27 33.
34. Saller C. F. Czupryna M. J. (1989) gamma-Aminobutyric acid, glutamate, glycine and taurine analysis using reversed-phase high-performance liquid chromatography and ultraviolet detection of dansyl chloride derivatives. J. Chromatogr. 487, 167 172.
35. Santa T., Aoyama C., Fukushima T., Imai K. Funatsu T. (2006) Suppression of thiol exchange reaction in the determination of reduced-form thiols by high-performance liquid chromatography with fluorescence detection after derivatization with fluorogenic benzofurazan reagent, 7-fluoro-2,1,3- benzoxadiazole-4-sulfonate and 4-aminosulfonyl-7-fluoro-2,1,3-benzoxadiazole. Biomed. Chromatogr. 20, 656 661.
36. Sershen H. Lajtha A. (1979) Inhibition pattern by analogs indicates the presence of ten or more transport systems for amino acids in brain cells. J. Neurochem. 32, 719 726.
37. Stack E. C., Ferro J. L., Kim J. et al. (2008) Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease. Biochim. Biophys. Acta 1782, 151 162.
38. Sun L., Xu S., Zhou M., Wang C., Wu Y. Chan P. (2010) Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice. Brain Res. 1335, 74 82.
39. Tremblay M. E., Saint-Pierre M., Bourhis E., Levesque D., Rouillard C. Cicchetti F. (2006) Neuroprotective effects of cystamine in aged parkinsonian mice. Neurobiol. Aging 27, 862 870.
40. Wade L. A. Brady H. M. (1981) Cysteine and cystine transport at the blood-brain barrier. J. Neurochem. 37, 730 734.
41. Wade L. A. Katzman R. (1975) Synthetic amino acids and the nature of L-DOPA transport at the blood-brain barrier. J. Neurochem. 25, 837 842.
42. Wang X., Sarkar A., Cicchetti F., Yu M., Zhu A., Jokivarsi K., Saint-Pierre M. Brownell A. L. (2005) Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. J. Neurol. Sci. 231, 57 66.